Aida Pharmaceuticals, Inc. (AIDA) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share; the S&P 500 usually sits near 20-25.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAida Pharmaceuticals, Inc. (AIDA) trades at $0.0003. Aida Pharmaceuticals, Inc. is a Chinese pharmaceutical company focused on developing, manufacturing, and marketing pharmaceutical and genetic products. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for AIDA: AIDA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AIDA against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
AIDA: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Aida Pharmaceuticals, Inc. (AIDA) Healthcare & Pipeline Overview
Aida Pharmaceuticals, Inc., based in China, formulates, tests, manufactures, and markets pharmaceutical and genetic products, including antibiotics, cardiovascular, and anti-cancer drugs. With a 9.4% profit margin and 50.3% gross margin, the company operates in the competitive Chinese pharmaceutical market, facing both growth opportunities and regulatory challenges.
What Is the Investment Thesis for AIDA?
Aida Pharmaceuticals, Inc. presents a mixed investment profile. The company's focus on the Chinese pharmaceutical market, with its aging population and increasing healthcare expenditure, offers growth potential. Aida's 9.4% profit margin and 50.3% gross margin indicate operational efficiency. Key growth catalysts include successful clinical trials and regulatory approvals for new drugs, particularly rh-Apo2l. However, the company faces risks associated with OTC market trading, intense competition from both domestic and international pharmaceutical companies, and potential regulatory changes in China. The company's high beta of 17.62 suggests significant volatility. Investors should carefully weigh these factors, considering the company's financial performance, market position, and the inherent risks of the pharmaceutical industry in China.
Based on FMP financials and quantitative analysis
AIDA Key Highlights
Aida Pharmaceuticals operates with a profit margin of 9.4%, reflecting its ability to generate earnings from its sales.
- The company maintains a gross margin of 50.3%, indicating efficient cost management in its manufacturing and sales processes.
- Aida Pharmaceuticals focuses on the Chinese pharmaceutical market, which is experiencing growth due to an aging population and increasing healthcare expenditure.
- Key products include Etimicin Sulfate (antibiotic) and rh-Apo2l (anti-cancer therapy), targeting significant health needs in China.
- The company's beta of 17.62 indicates high volatility compared to the overall market.
Who Are AIDA's Competitors?
AIDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $3.07 | +2.33% | — | |
| GELS Gelteq Limited Ordinary Shares | $0.79 | -7.37% | $7.23M | — |
| COSM COSM | $0.25 | -0.71% | $13.8M | — |
| BFRI Biofrontera Inc. | $1.59 | +9.25% | $20.4M | — |
| QNTM Quantum BioPharma Ltd. | $3.29 | -8.10% | $21.1M | — |
| AYTU Aytu BioPharma, Inc. | $2.02 | -1.22% | $21.7M | — |
| TXMD TherapeuticsMD, Inc. | $2.10 | -0.94% | $24.3M | — |
| SCYX SCYNEXIS, Inc. | $4.70 | -4.28% | $29.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AIDA's Key Strengths?
Established presence in the Chinese pharmaceutical market.
- Diverse product portfolio including antibiotics, cardiovascular drugs, and anti-cancer therapies.
- Manufacturing capabilities for various drug formulations.
- Existing relationships with healthcare providers and regulatory authorities.
What Are AIDA's Weaknesses?
Reliance on the Chinese market, limiting geographic diversification.
- Competition from both domestic and international pharmaceutical companies.
- Potential vulnerability to regulatory changes and pricing pressures.
- Limited brand recognition compared to larger multinational corporations.
What Could Drive AIDA Stock Higher?
Clinical trial results for rh-Apo2l expected in Q4 2026 could drive positive market sentiment.
- Expansion of distribution network into rural areas of China is expected to increase sales volume.
- Government initiatives to improve healthcare access in China could benefit Aida Pharmaceuticals.
What Are the Key Risks for AIDA?
Financial-distress signal — its Altman Z-Score of 0.41 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes in China could negatively impact the company's operations and profitability.
- Patent expirations and biosimilar competition could erode market share.
- Intense competition from both domestic and international pharmaceutical companies.
- The company's reliance on the Chinese market exposes it to economic and political risks specific to that country.
- The company's high beta of 17.62 indicates significant volatility.
What Are the Growth Opportunities for AIDA?
- Expanding rh-Apo2l Market Penetration: Aida Pharmaceuticals has the opportunity to increase the market penetration of its rh-Apo2l biopharmaceutical therapy for cancers within China. The Chinese cancer therapeutics market is projected to reach $45 billion by 2028, driven by rising cancer incidence and improved diagnostic capabilities. Successful clinical trials and regulatory approvals for additional cancer indications could significantly boost rh-Apo2l sales. The company's competitive advantage lies in its local manufacturing and distribution network, allowing it to offer rh-Apo2l at a competitive price point compared to imported therapies. Timeline: Ongoing, with potential for significant revenue growth within the next 3-5 years.
- Developing New Antibiotic Formulations: Aida Pharmaceuticals can leverage its expertise in antibiotic formulation to develop new and improved versions of existing antibiotics, addressing the growing problem of antibiotic resistance. The global market for antibiotics is expected to reach $44.6 billion by 2027. By focusing on developing formulations with improved efficacy and reduced side effects, Aida Pharmaceuticals can capture a significant share of the Chinese antibiotic market. The company's existing manufacturing infrastructure and regulatory expertise provide a competitive advantage. Timeline: 2-3 years for research and development, followed by clinical trials and regulatory approval.
- Strategic Partnerships and Acquisitions: Aida Pharmaceuticals can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring smaller firms with complementary products can accelerate growth and diversify revenue streams. The Chinese pharmaceutical market is consolidating, creating opportunities for strategic acquisitions. Aida Pharmaceuticals' financial stability and operational expertise make it an attractive partner for other companies. Timeline: Ongoing, with potential for significant impact within the next 1-2 years.
- Expanding into Rural Markets: Aida Pharmaceuticals can expand its distribution network to reach underserved rural markets in China. These markets represent a significant growth opportunity, as access to healthcare is often limited. By establishing partnerships with local distributors and healthcare providers, Aida Pharmaceuticals can increase its market share and improve healthcare access for rural populations. Government initiatives to improve rural healthcare infrastructure will further support this expansion. Timeline: 3-5 years, requiring investment in distribution infrastructure and local partnerships.
- Investing in Research and Development: Aida Pharmaceuticals can invest more heavily in research and development to discover and develop novel pharmaceutical products. This will allow the company to differentiate itself from competitors and capture a larger share of the market. Focusing on innovative therapies for prevalent diseases in China, such as cardiovascular disease and diabetes, can yield significant returns. Government support for pharmaceutical innovation provides additional incentives. Timeline: Long-term, requiring sustained investment and a focus on strategic research areas.
What Threats Does AIDA Face?
- Increasing competition from generic drug manufacturers.
- Potential for patent expirations and biosimilar competition.
- Changes in government regulations and healthcare policies.
- Fluctuations in currency exchange rates.
What Are AIDA's Competitive Advantages?
- Established presence and distribution network in mainland China.
- Expertise in formulating and manufacturing pharmaceutical products.
- Portfolio of both generic and specialty drugs.
- Relationships with key healthcare providers and regulatory authorities in China.
What Does AIDA Do?
Founded in 1999 and headquartered in Hangzhou, China, Aida Pharmaceuticals, Inc. is a pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. The company's product portfolio encompasses a range of therapeutic areas, including antibiotics, cardiovascular drugs, and anti-cancer therapies. Aida Pharmaceuticals provides its products in various forms, including powder for injection, liquid for intravenous injection, capsules, tablets, and ointments. Key products include Etimicin Sulfate, an injectable antibiotic, and rh-Apo2l, a biopharmaceutical therapy targeting cancers. Aida Pharmaceuticals operates within the Chinese pharmaceutical market, navigating a complex regulatory landscape and competitive environment. The company focuses on both generic and specialty drugs, aiming to address prevalent health needs in China. With 450 employees, Aida Pharmaceuticals strives to maintain a balance between innovation and affordability in its product offerings. The company's strategic focus remains on expanding its market presence within China while adhering to stringent quality control and regulatory standards.
What Products and Services Does AIDA Offer?
- Formulates pharmaceutical products, including antibiotics, cardiovascular drugs, and anti-cancer therapies.
- Conducts clinical testing to ensure the safety and efficacy of its products.
- Registers its pharmaceutical products with regulatory authorities in China.
- Manufactures pharmaceutical products in various forms, including injections, capsules, tablets, and ointments.
- Sells and markets its products to healthcare providers and patients in mainland China.
- Develops and commercializes genetic products, including biopharmaceutical therapies for cancers.
How Does AIDA Make Money?
- Develops and manufactures generic and specialty pharmaceutical products.
- Markets and sells these products directly to hospitals, clinics, and pharmacies in mainland China.
- Generates revenue through the sale of its pharmaceutical products.
- Reinvests a portion of its revenue into research and development to create new products.
What Industry Does AIDA Operate In?
Aida Pharmaceuticals operates within the Chinese pharmaceutical market, a rapidly growing sector driven by an aging population, increasing healthcare expenditure, and government initiatives to improve healthcare access. The market is characterized by intense competition from both domestic and international players, including generic drug manufacturers and innovative biopharmaceutical companies. Regulatory changes and pricing pressures are significant factors shaping the industry landscape. Aida Pharmaceuticals competes with companies like BLMS, BTTX, CANQF, CENBF, and MJNE, navigating a complex environment to maintain market share and profitability. The company's focus on both generic and specialty drugs positions it to address a broad range of healthcare needs in China.
Who Are AIDA's Key Customers?
- Hospitals and clinics throughout mainland China.
- Pharmacies and drug stores.
- Patients who purchase prescription medications.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 41 |
| 2026-08-27 | 41 |
| 2026-08-31 | 41 |
| 2026-09-04 | 41 |
| 2026-09-08 | 41 |
| 2026-09-11 | 41 |
What changed?
The score has stayed at 41.
Over the same 19 days the stock moved +0.0%.
Financial Health
Aida Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.41 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Aida Pharmaceuticals, Inc. stands at 23.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.4%, showing how much profit it generates from its asset base. AIDA trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.50x. A current ratio of 0.93 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Aida Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hangzhou, CN. The company is led by CEO Biao Jin. AIDA has traded publicly since 2005.
AIDA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established presence in the Chinese pharmaceutical market.
- Diverse product portfolio including antibiotics, cardiovascular drugs, and anti-cancer therapies.
- Manufacturing capabilities for various drug formulations.
- Existing relationships with healthcare providers and regulatory authorities.
Bear Case
- Reliance on the Chinese market, limiting geographic diversification.
- Competition from both domestic and international pharmaceutical companies.
- Potential vulnerability to regulatory changes and pricing pressures.
- Limited brand recognition compared to larger multinational corporations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AIDA Latest News
No recent news available for AIDA.
AIDA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AIDA.
Price Targets
Wall Street price target analysis for AIDA.
AIDA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AIDA; grades run from A+ (80-100) to F (below 30).
Leadership: Biao Jin
CEO
Biao Jin is the Chief Executive Officer of Aida Pharmaceuticals, Inc. He is responsible for managing the company's overall strategy, operations, and financial performance. His background includes extensive experience in the pharmaceutical industry, with a focus on manufacturing, sales, and marketing. He has been instrumental in guiding Aida Pharmaceuticals through periods of growth and expansion, overseeing the development and commercialization of key products. His leadership is characterized by a commitment to innovation, quality, and regulatory compliance. He manages a workforce of 450 employees.
Track Record: Under Biao Jin's leadership, Aida Pharmaceuticals has expanded its product portfolio and increased its market share in China. He has overseen the successful launch of several new products, including rh-Apo2l, a biopharmaceutical therapy for cancers. He has also implemented cost-saving measures and improved operational efficiency, contributing to the company's profitability. His strategic decisions have positioned Aida Pharmaceuticals for continued growth in the Chinese pharmaceutical market.
AIDA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aida Pharmaceuticals may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial information available and may be subject to greater risks. Trading on the OTC Other tier does not necessarily indicate that a company is fraudulent or illegitimate, but it does suggest that investors should exercise extra caution and conduct thorough due diligence before investing. Companies in higher tiers generally have more stringent listing requirements and provide more comprehensive financial disclosures, offering investors greater transparency and protection.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in Aida Pharmaceuticals.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in exiting positions.
- The OTC Other tier has less stringent listing requirements, increasing the risk of fraud or mismanagement.
- The company's operations are concentrated in China, exposing it to regulatory and economic risks specific to that country.
- The pharmaceutical industry is highly competitive, and Aida Pharmaceuticals faces competition from larger and more established companies.
- Verify the company's registration and good standing with relevant regulatory authorities.
- Obtain and review any available financial statements, even if limited.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Monitor news and public filings for any red flags or potential risks.
- Consult with a qualified financial advisor before investing.
- The company has been in operation since 1999, suggesting a degree of stability.
- Aida Pharmaceuticals has a portfolio of pharmaceutical products that are sold in mainland China.
- The company employs 450 people, indicating a significant operational scale.
- The company has a CEO, Biao Jin, which suggests a formal management structure.
What Investors Ask About Aida Pharmaceuticals, Inc. (AIDA) — Healthcare
Is AIDA a good stock?
Stock Expert AI does not rate AIDA buy, sell or hold. Aida Pharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about AIDA stock?
As of March 17, 2026, formal analyst coverage of AIDA is limited due to its OTC listing. Key valuation metrics like P/E ratio are currently at 0.00.
What are the key factors to evaluate for AIDA?
Evaluate AIDA on fundamentals, analyst consensus, and risk factors. P/E: 0.00x vs the S&P 500's ~20-25x. Aida Pharmaceuticals, Inc. presents a mixed investment profile. Not financial advice.
How frequently does AIDA data refresh on this page?
AIDA's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven AIDA's recent stock price performance?
Aida Pharmaceuticals, Inc. (AIDA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese pharmaceutical market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AIDA overvalued or undervalued right now?
Aida Pharmaceuticals, Inc. (AIDA) trades at 0.00x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AIDA?
Yes, most major brokerages offer fractional shares of Aida Pharmaceuticals, Inc. (AIDA) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AIDA's earnings and financial reports?
Aida Pharmaceuticals, Inc. (AIDA) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for AIDA earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing.
- Analyst coverage is sparse, making it difficult to assess market sentiment.
- The Chinese pharmaceutical market is subject to regulatory changes and competitive pressures.